Physician profile
Daniel T Friedman
NPI 1538180252
$3,410.52
in general payments reported to CMS, 2019-2025
21 companies · $2,230 in 2025
The $2,230 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $99.95 · 2021: $224 · 2022: $99.95 · 2023: $197 · 2024: $409 · 2025: $2,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,350 · Food and Beverage: $1,234 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,350.00 |
| Food and Beverage | $1,233.91 |
| Education | $252.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,388.41 | 2024-2025 | |
| Janssen Biotech, INC. | $537.53 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Daiichi Sankyo INC. | $303.29 | 2021-2025 | Enhertu |
| Sobi, INC | $135.21 | 2024-2025 | |
| Genzyme Corporation | $123.94 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $121.75 | 2024-2025 | Imfinzi, Tagrisso |
| Seagen INC. | $99.99 | 2023 | |
| Incyte Corporation | $83.99 | 2024 | |
| Rigel Pharmaceuticals, INC. | $76.95 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Medtronic, INC. | $74.79 | 2025 | Emprint, Synchromedii |
| Novartis Pharmaceuticals Corporation | $73.49 | 2024-2025 | |
| Cti Biopharma Corp. | $66.20 | 2023 | Vonjo |
| Glaxosmithkline, LLC. | $61.14 | 2025 | Jemperli, Ojjaara |
| Merck Sharp & Dohme LLC | $60.61 | 2024-2025 | Keytruda, Lynparza |
| Abbvie INC. | $49.41 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $43.35 | 2024-2025 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $30.34 | 2025 | Reblozyl |
| Pharmaessentia USA Corporation | $28.89 | 2025 | Besremi |
| Natus Medical Incorporated | $25.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2019 | |
| Pfizer INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.